A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Silodosin (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- Sponsors JW Pharmaceutical
- 08 Mar 2017 Status changed from recruiting to completed.
- 16 Apr 2014 New trial record